Adagrasib
Krazati (adagrasib) is a small molecule pharmaceutical. Adagrasib was first approved as Krazati on 2022-12-12. It is used to treat non-small-cell lung carcinoma in the USA. It is known to target GTPase KRas.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
|---|---|
| neoplasms | D009369 |
| respiratory tract diseases | D012140 |
Trade Name
FDA
EMA
Krazati
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Adagrasib
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| KRAZATI | Bristol Myers Squibb | N-216340 RX | 2022-12-12 | 1 products, RLD, RS |
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| krazati | New Drug Application | 2024-07-11 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| non-small-cell lung carcinoma | — | D002289 | — |
Agency Specific
FDA
EMA
Expiration | Code | ||
|---|---|---|---|
ADAGRASIB, KRAZATI, MIRATI THERAPS | |||
| 2029-12-12 | ODE-352 | ||
| 2027-12-12 | NCE | ||
Patent Expiration
Patent | Expires | Flag | FDA Information |
|---|---|---|---|
| Adagrasib, Krazati, Mirati Theraps | |||
| 10689377 | 2037-05-17 | DS, DP | U-3490 |
HCPCS
No data
Clinical
Clinical Trials
34 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Non-small-cell lung carcinoma | D002289 | — | — | 7 | 9 | 4 | — | 1 | 17 |
| Neoplasm metastasis | D009362 | EFO_0009708 | — | 5 | 5 | 1 | — | 1 | 9 |
| Colorectal neoplasms | D015179 | — | — | 7 | 4 | 1 | — | — | 8 |
| Lung neoplasms | D008175 | — | C34.90 | 3 | 3 | 1 | — | 1 | 7 |
| Colonic neoplasms | D003110 | — | C18 | 3 | 1 | 1 | — | — | 4 |
| Rectal neoplasms | D012004 | — | — | — | — | 1 | — | — | 1 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Neoplasms | D009369 | — | C80 | 13 | 7 | — | — | 1 | 16 |
| Pancreatic neoplasms | D010190 | EFO_0003860 | C25 | 2 | 1 | — | — | — | 2 |
| Brain neoplasms | D001932 | EFO_0003833 | C71 | — | 1 | — | — | — | 1 |
| Biliary tract neoplasms | D001661 | — | C24.9 | 1 | 1 | — | — | — | 1 |
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Renal cell carcinoma | D002292 | EFO_0000376 | — | 2 | — | — | — | — | 2 |
| Gastrointestinal neoplasms | D005770 | — | C26.9 | 1 | — | — | — | — | 1 |
| Intestinal neoplasms | D007414 | — | C26.0 | 1 | — | — | — | — | 1 |
| Pancreatic ductal carcinoma | D021441 | — | — | 1 | — | — | — | — | 1 |
| Kidney neoplasms | D007680 | EFO_0003865 | C64 | 1 | — | — | — | — | 1 |
| Healthy volunteers/patients | — | — | — | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Small cell lung carcinoma | D055752 | — | — | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Adagrasib |
| INN | adagrasib |
| Description | Adagrasib, sold under the brand name Krazati, is an anticancer medication used to treat non-small cell lung cancer. Adagrasib is an inhibitor of the RAS GTPase family. It is taken by mouth. It is being developed by Mirati Therapeutics.
|
| Classification | Small molecule |
| Drug class | Kirsten rat sarcoma (KRAS) inhibitors |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | C=C(F)C(=O)N1CCN(c2nc(OC[C@@H]3CCCN3C)nc3c2CCN(c2cccc4cccc(Cl)c24)C3)C[C@@H]1CC#N |
Identifiers
| PDB | — |
| CAS-ID | 2326521-71-3 |
| RxCUI | — |
| ChEMBL ID | CHEMBL4594350 |
| ChEBI ID | — |
| PubChem CID | 138611145 |
| DrugBank | DB15568 |
| UNII ID | 8EOO6HQF8Y (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
KRAS
KRAS
Organism
Homo sapiens
Gene name
KRAS
Gene synonyms
KRAS2, RASK2
NCBI Gene ID
Protein name
GTPase KRas
Protein synonyms
c-K-ras, c-Ki-ras, c-Kirsten-ras protein, cellular c-Ki-ras2 proto-oncogene, cellular transforming proto-oncogene, K-Ras 2, K-ras p21 protein, Ki-Ras, Kirsten rat sarcoma viral oncogene homolog, Kirsten rat sarcoma viral proto-oncogene, KRAS-ENOPH fusion, Kras-Enoph1 fusion protein, oncogene KRAS2, PR310 c-K-ras oncogene, proto-oncogene GTPase, transforming protein p21, v-Ki-ras2 Kirsten rat sarcoma 2 viral oncogene homolog
Uniprot ID
Mouse ortholog
Kras (16653)
GTPase KRas (P32883)
Variants
No data
Financial
Revenue by drug
$
€
£
â‚£
Krazati – Bristol Myers Squibb
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Estimated US medical usage
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 2,152 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
887 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use